HEMADY (dexamethasone) by Bridge Therapeutics is corticosteroid hormone receptor agonists [moa]. First approved in 2019.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
HEMADY is an oral tablet formulation of dexamethasone, a corticosteroid hormone receptor agonist approved in October 2019. It works by binding to glucocorticoid receptors to suppress inflammatory and immune responses. The product is indicated for conditions requiring corticosteroid therapy, though specific labeled indications are not detailed in available data.
Product is at peak lifecycle stage with minimal Part D penetration, suggesting either narrow indication focus or limited market adoption, which may constrain commercial team expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Worked on HEMADY at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHEMADY currently shows zero linked job openings, indicating minimal active hiring despite peak lifecycle status. Working on this product offers stability through 2037 patent protection but limited growth trajectory, making it suitable for career roles focused on brand optimization and risk management rather than market expansion.